Efficacy and safety of cilostazol in decreasing progression of cerebral white matter hyperintensities—A randomized controlled trial

INTRODUCTION: Cerebral small vessel disease (SVD) is an important cause of dementia that lacks effective treatment. We evaluated the efficacy and safety of cilostazol, an antiplatelet agent with potential neurovascular protective effects, in slowing the progression of white matter hyperintensities (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ip, Bonaventure Y. M., Lam, Bonnie Y. K., Hui, Vincent M. H., Au, Lisa W. C., Liu, Mandy W. T., Shi, Lin, Lee, Vivian W. Y., Chu, Winnie C. W., Leung, Thomas W., Ko, Ho, Mok, Vincent C. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793825/
https://www.ncbi.nlm.nih.gov/pubmed/36583111
http://dx.doi.org/10.1002/trc2.12369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793825/
https://www.ncbi.nlm.nih.gov/pubmed/36583111
http://dx.doi.org/10.1002/trc2.12369

Ejemplares similares